110 related articles for article (PubMed ID: 20004272)
1. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
Kroll R; Reape KZ; Margolis M
Contraception; 2010 Jan; 81(1):41-8. PubMed ID: 20004272
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
[TBL] [Abstract][Full Text] [Related]
3. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
Bannemerschult R; Hanker JP; Wünsch C; Fox P; Albring M; Brill K
Contraception; 1997 Nov; 56(5):285-90. PubMed ID: 9437556
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a 21/7-active combined oral contraceptive with continuous low-dose ethinyl estradiol.
Kroll R; Ackerman R; Feldman R; Howard B; Weiss H; Hsieh J; Ricciotti N
Contraception; 2016 Mar; 93(3):249-56. PubMed ID: 26499407
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
[TBL] [Abstract][Full Text] [Related]
7. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
[TBL] [Abstract][Full Text] [Related]
9. Effect of Extended 30 μg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 μg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
Gersten J; Hsieh J; Weiss H; Ricciotti NA
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):635-642. PubMed ID: 27287084
[TBL] [Abstract][Full Text] [Related]
10. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Jensen JT; Garie SG; Trummer D; Elliesen J
Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
Anderson FD; Gibbons W; Portman D
Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
[TBL] [Abstract][Full Text] [Related]
12. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
Poindexter A; Reape KZ; Hait H
Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111
[TBL] [Abstract][Full Text] [Related]
14. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Reid RL; Fortier MP; Smith L; Mirkin S; Grubb GS; Constantine GD
Contraception; 2010 Dec; 82(6):497-502. PubMed ID: 21074011
[TBL] [Abstract][Full Text] [Related]
15. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
Kaunitz AM; Archer DF; Mishell DR; Foegh M
Am J Obstet Gynecol; 2015 Mar; 212(3):318.e1-8. PubMed ID: 25220709
[TBL] [Abstract][Full Text] [Related]
18. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive.
Westhoff CL; Hait HI; Reape KZ
Contraception; 2012 Mar; 85(3):235-9. PubMed ID: 22067763
[TBL] [Abstract][Full Text] [Related]
19. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG).
Archer DF; Maheux R; DelConte A; O'Brien FB
Contraception; 1997 Mar; 55(3):139-44. PubMed ID: 9115001
[TBL] [Abstract][Full Text] [Related]
20. Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
Lobo Abascal P; Luzar-Stiffler V; Giljanovic S; Howard B; Weiss H; Trussell J
Eur J Contracept Reprod Health Care; 2016; 21(1):88-91. PubMed ID: 26115381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
